Novexel
Paris
France
17 articles about Novexel
-
Forest Laboratories, Inc. Announces Acquisition From Novexel of Additional Rights Related to NXL 104, a Novel Broad-Spectrum Beta-Lactamase Inhibitor
12/23/2009
-
AstraZeneca PLC (JOBS) to Buy Novexel for $350 Million
12/23/2009
-
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
11/6/2009
-
Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
9/11/2009
-
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
5/18/2009
-
Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
3/26/2009
-
Novexel's NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
3/3/2009
-
Novexel's NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
11/12/2008
-
Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Meeting
10/27/2008
-
Novexel To Present Five Posters At The Joint Annual Interscience Conference On Antimicrobial Agents And Chemotherapy And The Infectious Disease Society Of America (ICAAC/IDSA) Meeting
10/24/2008
-
Novexel Appoints Dr. Kenneth Coleman as Chief Scientific Officer
10/24/2008
-
Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10/23/2008
-
Novexel Discontinues Development of NXL 101
6/30/2008
-
Novexel Initiates Phase II Trial of NXL103
11/14/2007
-
Novexel Raises €50 Million In A Series B Round
1/8/2007
-
Novexel Announces Formation Of Its Scientific Advisory Board
3/21/2006
-
Novexel Begins Phase I Trial, Gathers In Milestone Payment
10/12/2005